TRACK A
Transforming Market Insights in Pharma with AI-Driven Analysis
Utilizing AI-powered analysis of clinical data to uncover crucial market trends and opportunities in the pharmaceutical industry.
Presented by LARVOL
TRACK B
From Insights to Impact: How Agentic AI Empowers Pharma Competitive Intelligence
Until now, AI systems, including advanced large language models (LLMs), have excelled at generating insights, summarizing complex data, and responding effectively to human prompts. Yet these tools have always depended on explicit human instructions and have been unable to independently initiate tasks or proactively execute strategic decisions.
Agentic AI changes this dynamic. It empowers AI agents to autonomously recognize meaningful patterns, proactively uncover insights, and even recommend or execute strategic actions, all within predefined goals and guardrails established by human decision-makers.
In this engaging session, David Seuss, founder and CEO of Northern Light, will share practical examples of how Agentic AI is reshaping market research and competitive intelligence in pharma, empowering organizations to move beyond reacting to market changes toward actively driving strategic decisions. Mr. Seuss will illustrate how Agentic AI:
• Accelerates strategic responses to rapidly shifting market conditions.
• Enables highly personalized insights at scale.
• Streamlines competitive intelligence through autonomous monitoring and analysis of market dynamics.
Presented by Northern Light
TRACK C
Winning Strategies: Best CI Practices to Drive Launch and Sustained Success in the Biosimilar Market
The global biosimilars market is projected to reach approximately US$136 billion by 2028, driven by a robust CAGR of 35% between 2022 and 2028. Over 40 blockbuster biologics are expected to lose market exclusivity by 2032, fueling intense competition among biosimilar-focused companies vying for a significant share of this expanding market.
However, the development and commercialization of biosimilars differ substantially from that of generic NMEs. As a result, modern biosimilar manufacturers must stay attuned to key market trends, technological advancements, shifting dynamics, and global collaborations.
This session will shed light on the tailored competitive intelligence (CI) needs of biosimilar companies and how they diverge from traditional approaches used in innovative drug development market monitoring. It aims to help biosimilar manufacturers reassess their essential CI requirements and build a compelling case for securing the necessary budget from leadership teams.
Presented by AdametNext